TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$230 Million

Generation Bio Co.

Initial Public Offering

Bookrunner, June 2020

Generation Bio Co.

Generation Bio Co. is a genetic medicines company developing a new generation of non-viral gene therapies. Generation’s gene therapy platform is comprised of three essential components: a high-capacity, non-viral ceDNA construct, a cell-targeted lipid nanoparticle (ctLNP) delivery system and a scalable manufacturing process. The Company is advancing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. Generation’s two most advanced candidates address phenylketonuria (PKU) and Hemophilia A. The applications of its platform extend beyond the liver and retina and Generation plans to develop a portfolio of candidates that address diseases in skeletal muscle, CNS and oncology.